Epitalon

What Is Epitalon?

Epitalon's research lineage runs back to 1973, when Soviet researchers first described “Epithalamin” — a polypeptide extract from the pineal gland — in published research. The scientist most associated with developing this line of work is Vladimir Khavinson, whose research into extending functional longevity began in the late 1970s under the Soviet military, which was specifically interested in helping soldiers and cosmonauts withstand extreme physiological stress. Alongside collaborator Vladimir Anisimov, Khavinson's research eventually centered at what became the St. Petersburg Institute of Bioregulation and Gerontology. Epitalon itself — a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly — was synthesized to match the amino acid composition identified within Epithalamin, the original bovine pineal-gland extract. See its full discovery history.

Research Focus

Epitalon is now the most extensively studied of the Khavinson-lineage bioregulator peptides, and its research program has stayed close to its original focus on aging and pineal-gland biology. A substantial share of the published literature examines its relationship to telomerase, the enzyme responsible for maintaining the protective caps (telomeres) on chromosomes, since telomere shortening is one of the most-studied mechanisms of cellular aging. It sits in KYIN's Longevity & Cellular Health category alongside SS-31 and NAD+. See our Longevity & Cellular Health research overview, or how it compares to SS-31. See also our Khavinson bioregulator peptides overview for how it fits alongside Pinealon, Cartalax, Thymalin, and Vilon.

• Telomerase activity research
• Pineal gland / melatonin regulation studies
• Cellular senescence research

Clinical & Preclinical Trial Data

Khavinson and Morozov (2003) followed a cohort of 266 elderly individuals for 6–8 years after receiving short courses of peptide bioregulators, reporting mortality reduction ranging from 1.6× (Epitalon-based regimen alone) up to roughly 4× in the most intensive combined-regimen group, versus untreated controls. This and most other Epitalon research comes from Khavinson's own institute (the St. Petersburg Institute of Bioregulation and Gerontology) and Russian-affiliated journals, and has not been independently replicated in a large Western multi-center trial — it should be read as early domestic cohort evidence, not evidence of the same strength as an FDA-reviewed trial. Separately, a 2025 laboratory study using human cell lines (Al-dulaimi et al., Biogerontology) found that Epitalon treatment increased telomere length across both normal cells (fibroblasts, mammary epithelial cells) and breast-cancer-derived cell lines, acting through telomerase upregulation in some cell types and the alternative lengthening of telomeres (ALT) pathway in others — laboratory evidence consistent with the proposed mechanism, though in-vitro cell-line data of this kind is distinct from, and not a substitute for, evidence of effects in living humans.

In July 2026, an FDA advisory committee recommended Epitalon for the 503A compounding bulks list — a non-binding vote, not FDA drug approval. Read what it actually means →

Explore the Full Epitalon Research Cluster

Every angle of Epitalon research in one place:

• Mechanism of Action — telomerase activation and pineal gland research
• Discovery & Research History — from Soviet pineal-extract research to a synthetic tetrapeptide
• Epitalon vs SS-31 — two branches of cellular-aging research compared
• Epitalon vs NAD+ — a disputed gene-regulatory peptide versus an established metabolic coenzyme
• Bioregulator Peptides Overview — how Epitalon relates to the Khavinson-lineage family
• Certificate of Analysis Guide — how to read Epitalon's purity testing
• Product & Pricing

Availability

Epitalon is part of KYIN Peptides' standard catalogue — see the product page for pricing, or contact us to order.